We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this ...

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the ...

Dutch scientists at Leiden University’s medical centre have discovered the genetic variation which protects against type 1 diabetes, bringing a cure for the disease a step closer. The discovery, ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

In other significant trading activity, ARK continued to bolster its position in CRISPR Therapeutics AG (NASDAQ: CRSP ), purchasing 24,324 shares across its ARKK and ARKG ETFs, totaling nearly $1 ...

Vaccine Research Market Governments and private entities are heavily investing in vaccine research and development.US, NY, UNITED STA ...

Illumina Inc. and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250 ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Discover the latest breakthroughs in migraine treatment for 2025, including CGRP inhibitors, AI-powered personalized plans, ...